Neuland Laboratories Limited has informed the Exchange regarding a press release dated May 12, 2026, titled "Press Release on the Financial Results of the Company for the quarter and year ended March 31, 2026".
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neuland Laboratories reported exceptional Q4FY26 results with total income of Rs.788.7 crore, up 134.9% YoY, and EBITDA of Rs.319.4 crore, up 448.6% YoY. EBITDA margin expanded sharply to 40.5% from 17.3% in Q4FY25, a gain of 2316 basis points. Profit after tax rose to Rs.212.5 crore versus Rs.27.7 crore in the prior year quarter. Management noted good short-to-medium-term business visibility anchored by commercial and near-commercial molecules, and said investments in peptide manufacturing and a new R&D centre are proceeding on plan. The company will host an earnings call on May 12, 2026.
The sharp improvement in margins and profitability signals strong operational execution and likely one-time or accelerated revenue recognition; however, the extreme magnitude of the swing warrants scrutiny on sustainability when assessing long-term investment thesis.